Author

N. Wyhs

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:genetic perturbation / CRISPR· 2 Research Focus:cell type annotation· 1 Assay:CRISPR screen· 1

Frequent Co-Authors

B. Vogelstein· 3 shared C. Bettegowda· 3 shared K. W. Kinzler· 3 shared N. Papadopoulos· 3 shared S. Zhou· 3 shared A. L. Cook· 2 shared B. Ptak· 2 shared E. Watson· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

B. Vogelstein

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape

A. L. Cook, S. Sur, L. Dobbyn, E. Watson, J. D. Cohen, B. Ptak, B. S. Lee, S. Paul, E. Hsiue, M. Popoli, B. Vogelstein, N. Papadopoulos, C. Bettegowda, K. Gabrielson, S. Zhou, , N. Wyhs

A SMG1 inhibitor disrupts nonsense-mediated decay, increasing expression of neoantigens from truncating mutations and enhancing immune targetable peptides on cancer cells.

bioRxiv · Dec 28, 2023Cancer Biology

ME3BP-7 is a targeted cytotoxic agent that rapidly kills pancreatic cancer cells expressing high levels of monocarboxylate transporter MCT1

J. Rincon-Torroella, M. Dal Molin, B. Mog, G. Han, E. Watson, N. Wyhs, S. Ishiyama, T. Ahmedna, I. Minn, N. S. Azad, C. Bettegowda, N. Papadopoulos, K. W. Kinzler, S. Zhou, B. Vogelstein, , S. Sur

ME3BP-7 is a novel 3BP formulation that resists serum degradation and kills MCT1-high pancreatic cancer cells with low toxicity in mice.

bioRxiv · Jul 23, 2023Cancer Biology

Novel tumorigenic FOXM1-PTAFR-PTAF axis revealed by multi-omic profiling in TP53/CDKN2A-double knockout human gastroesophageal junction organoid model

H. Zhao, Y. Cheng, A. Kalra, K. Ma, Y. Zheng, B. Ziman, C. Tressler, K. Glunde, E. J. Shin, S. Ngamruengphong, M. Khashab, V. Singh, R. A. Anders, S. Jit, N. Wyhs, , S. J. Meltzer

bioRxiv · May 10, 2022 · PreprintCancer Biology

An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer Drugs

A. L. Cook, N. Wyhs, S. B. Sur, B. Ptak, M. Popoli, L. Dobbyn, T. Papadopoulos, C. Bettegowda, N. Papadopoulos, B. Vogelstein, S. Zhou, K. W. Kinzler

The paper creates an isogenic cell line panel for drug screening, finding that most lines did not fully inactivate genes but a subset had biallelic disruptions, enabling drug response testing.

bioRxiv · Aug 6, 2021Cancer Biology

PHENOTYPIC CHARACTERIZATION OF TWO NOVEL CELL LINE MODELS OF CASTRATION RESISTANT PROSTATE CANCER.

M. C. Haffner, A. Bhamidipati, H. K. Tsai, D. M. Esopi, A. M. Vaghasia, J.-Y. Low, R. A. Patel, G. Guner, M.-T. Pham, N. Castagna, J. Hicks, N. Wyhs, R. Aebersold, A. M. De Marzo, W. G. Nelson, , S. Yegnasubramanian

This study develops two novel castration-resistant prostate cancer cell lines and characterizes their transcriptomic and proteomic profiles to understand resistance mechanisms.

bioRxiv · Jul 4, 2021 · PreprintCancer Biology